IHV Lifetime Achievement Awards

2014 Lifetime Achievement Award for Scientific Contributions

Dr. Paul

William E. Paul, MD

William Paul is best known for his path-breaking work on cytokine biology including the discovery of interleukin-4, an extensive body of research on this cytokine that established it as the critical regulator of allergic inflammatory diseases and for establishing the mechanisms through which naïve CD4 T cells differentiate into Th effector cells.  He has also made major contributions to the fields of T cell recognition of antigen, immunoglobulin class switching and B cell activation.

William Paul is Chief of the Laboratory of Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health and a National Institutes of Health Distinguished Investigator.  From 1994 to 1997, he was Director of the NIH Office of the AIDS Research. During Paul’s tenure as OAR Director, he was mainly responsible for a new emphasis on HIV vaccine research and development. He proposed and obtained resources for the creation of the Vaccine Research Center on the NIH campus.

Dr. Paul is a member of the U.S. National Academy of Sciences and of its Institute of Medicine.  He is a fellow of the American Academy of Arts and Sciences.  He received the 1980 Founder's Prize of the Texas Instruments Foundation, the 1988 Life Sciences Award from the Federation of American Societies for Experimental Biology, Lifetime Achievement Awards from the American Association of Immunologists and the International Cytokine Society, the 2008 Max Delbruck Medal and the 2009 Clemens von Pirquet Medal.  He is a Raymond & Beverly Sackler Senior Professor by Special Appointment at Tel Aviv University and an Adjunct Professor of Pathology and Laboratory Medicine at the University of Pennsylvania School of Medicine.  He served as editor-in-chief of the Annual Review of Immunology for its first 30 volumesand is the editor of the advanced textbook, Fundamental Immunology, the seventh edition of which has recently appeared. 

2014 Lifetime Achievement Award for Public Service

Dr. Martin

John C. Martin, PhD

John C. Martin has served as chairman and CEO of Gilead Sciences since May 2008. He was president and CEO from April 1996 through May 2008. He joined the company in October 1990 as vice president for research and development. From 1984 to 1990, he was the head of antiviral chemistry at Bristol-Myers Squibb. Prior to that, he was with Syntex Corporation from 1978 to 1984.  His research and career have focused on antiviral therapeutics, and he has contributed to the successful development of ganciclovir and cidofovir (CMV retinitis); oseltamivir (influenza); adefovir and tenofovir (hepatitis B); didanosine, stavudine, tenofovir, emtricitabine, Truvada®, Atripla®, Complera®, and Stribild® (HIV/AIDS); and Sovaldi® (hepatitis C).

Dr. Martin was President of the International Society for Antiviral Research from 1998 through 2000, Chairman of the Board of Directors of the BayBio – an industry organization - from 1999 through 2001, and Chairman of the Board of Directors of the California Healthcare Institute from 2005 through 2006 and 2009. He served on the National Institute of Allergy & Infectious Diseases Council from 2000 through 2003, on the Board of Directors of the Biotechnology Industry Organization from 2003 through 2005, on the Board of Directors of Gen-Probe Incorporated from 2007 through 2012, on the Board of Trustees of the University of Chicago from 2002 through 2008, on the Board of Trustees of the Golden Gate University from 2003 through 2006, and on the External Scientific Advisory Board of the University of California School of Global Health in 2008. Additionally, Dr. Martin served on the Centers for Disease Control/Health Resources and Services Administrations Advisory Committee on HIV and STD Prevention and Treatment from 2004 through 2007 and was a member of the Presidential Advisory Council on HIV/AIDS from 2006 through July of 2009. He is currently a member of the Board of Directors of California Healthcare Institute and also serves on the University of Southern California Board of Trustees.

Dr. Martin received a PhD in organic chemistry from the University of Chicago, an MBA in Marketing from Golden Gate University and a BS in chemical engineering from Purdue University. He received the Isbell Award of the American Chemical Society for his applications of carbohydrate chemistry to the design of medicinally active nucleosides and nucleotides. He also is the recipient of the International Society for Antiviral Research's Gertrude B. Elion award for Scientific Excellence. In 2008, he was inducted into the National Academy of Engineering of the National Academies.